AlphAIAlphAI — Financial news for AI agents
prnewswire.comOCT 11 min read$CLB

CORE LABORATORIES ANNOUNCES TIMING OF THIRD QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL

Core Laboratories (CLB) will release Q3 2026 earnings after market close on October 28, 2026, and host a conference call the next day. CEO Larry Bruno, CFO Chris Hill, and SVP Gwen Gresham will discuss financial and operational results. The webcast and replay will be available on the company's website.

Original reporting
prnewswire.com
Published Oct 1, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CORE LABORATORIES ANNOUNCES TIMING OF THIRD QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL — source image
Source · prnewswire.com
Decision brief

The 30-second read

$CLBNeutralLow
01

Why it matters

The earnings schedule sets the timeline for investors to assess the company's performance for Q3 2026.

02

Market read

A routine earnings release announcement with limited immediate market impact.

03

What to watch

Potential hidden guidance or surprise in the upcoming earnings could move the stock sharply.

Relevance 5/10Novelty 4/10Timing: pre‑market on Oct 28, 2026

Background

Core Laboratories provides reservoir description and production enhancement services for the petroleum industry.

Company-level read

Ticker impact

$CLBNeutralHigh confidence
Context

Core Laboratories announced the date and time of its Q3 2026 earnings release and conference call.

Expected impact

likely neutral as investors await the actual earnings numbers.

Evidence & confidence

Without earnings figures or guidance, the market typically shows little movement until the release.

Market effects

Sector

None immediate; the timing may affect short‑term trading activity in the oilfield services sector.

Regional

Limited to U.S. investors tracking energy services earnings.

Global

Minimal, as the news is a routine earnings schedule.

Counterpoint

What could challenge this read

If the market overreacts to the timing, a short‑term pullback could present a buying opportunity.

Key entities

  • Executive
    Larry Bruno

    Chairman and CEO of Core Laboratories.

  • Executive
    Chris Hill

    Chief Financial Officer of Core Laboratories.

Read at source← All news

Related articles

JUL 29
$CLBMed

CORE LAB REPORTS SECOND QUARTER 2026 RESULTS

Core Laboratories (NYSE:CLB) reported Q2 2026 revenue of $124.6M, up 2% sequentially but down 4% year over year. Operating income was $9.2M, or $9.4M ex-items. GAAP EPS was $0.13, EPS ex-items $0.11. Free cash flow was $3.1M. The company repurchased 214,712 shares for $2.7M and announced a Q3 dividend.

prnewswire.com6 min
JUL 29
$CLBMed

CORE LAB REPORTS SECOND QUARTER 2026 RESULTS

Core Laboratories Inc. /DE/ (CLB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS SECOND QUARTER 2026 RESULTS: • REVENUE OF $124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR • OPERATING INCOME OF $9.2 MILLION; EX-ITEMS, $9.4 MILLION, UP 42% SEQUENTIALLY AND DOWN 36% YEAR-OVER-YEAR • GAAP EARNINGS

SEC EDGAR 8-K6 min
OCT 21
$NVSHighAI 8/10

Novartis (NVS) Grew Sales Again as Entresto Fell 50%, Can Remibrutinib Carry It?

Novartis (NVS) reported a 1% increase in Q2 net sales, with newer drugs like Kisqali and Scemblix growing, offsetting Entresto's 50% decline. The company won a second US approval for Rhapsido (remibrutinib) for chronic hives. Investors focus on upcoming MS data and Q3 results, as pipeline misses have raised pressure on growth prospects. NVS trades at 17.4x 2026 earnings, with consensus expecting a 1.65% EPS dip this year.

insidermonkey.com3 min